放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.     

1988～1992年兰空机关大院计划免疫工作情况

1988～1992年我们坚持开展儿童计划免疫及新兵预防接种工作,增强了集体免疫力,提高了健康水平,现将主要情况分析如下: 1 基本情况 兰空机关大院每年有500多名儿童及100多名新兵为接种重点。对学龄前儿童进行“四     

低血钾致单纯性ST段下垂型下移1例

患者 ,女 ,5 1岁。因间歇性肢体麻木 3周 ,伴胸闷憋气加重 1天来院就诊。既往有高血压病史 1年 ,近半年口服吲达帕胺片 (商品名 :寿比山 ) 2 .5ｍｇｑｄ。体检 :血压 110 /70ｍｍＨｇ (1ｍｍＨｇ =0 .133ｋＰａ) ,心率 70次 /ｍｉｎ ,律齐 ,无病理性杂音。实验室检查 :血Ｋ+2 .77ｍｍｏｌ/Ｌ ,Ｎａ+134.1ｍｍｏｌ/Ｌ ,Ｃｌ-94 .8ｍｍｏｌ/Ｌ。临床诊断 :低钾血症。心电图 (图1Ａ)示 :窦性心律 ,心率 73次 /ｍｉｎ ,Ｐ Ｒ间期 0 .16ｓＳＴⅡ ,Ⅲ ,ａＶＦ ,Ｖ3,Ｖ5,Ｖ6 下垂型下移 >0 .10ｍＶ ,ＳＴＶ4 下移 0 .15ｍＶ ,ＴⅡ ,ａＶＦ ,Ｖ2～ 6…     

放射线联合p53基因及内皮抑素治疗小鼠前列腺癌皮下移植瘤

Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.     

原发性肝癌合并门静脉瘤栓的化疗栓塞治疗

将116例合并门静脉主干或左右大分支瘤栓的原发性肝癌分为三组,A组32例,采用单纯肝动脉灌注化疗法;B组66例,采用常规肝动脉化疗加碘油和明胶海绵栓塞法;C组18 例,采用肝段或亚肝段动脉化疗加碘油和明胶海绵栓塞。结果示,A组6、12、18和24个月生存率分别为25 .0%(8/32)、9 .4%(3/32)、3 1%(1/32)和0(0/32),门脉瘤栓消失率为3 .1% (1/32); B 组6、12、18 和24 个月生存率分别为53 .0% (35/66)、25. 8% (17/66)、9 .1%(6/66)和3 0%(2/66),门脉瘤栓消失率为19 .7%(13/66);C组6、12、18 和24 个月生存率分别为72 .2%(13/18)、44 .4%(8/18)、22. 2%(4/18)和11. 1%(2/18),门脉瘤栓消失率为44 .4%(8/18)。各组生存率(P<0 .05)及门脉瘤栓消失率(P<0 .01)差异均有统计学意义。初步观察结果提示,经肝动脉化疗及栓塞法是治疗合并门脉瘤栓原发性肝癌的有效方法,且栓塞法优于单纯灌注化疗法,特别是肝段或亚肝段动脉化疗栓塞法疗效更好。     

乙酰葛根素对于大鼠局灶性脑缺血再灌注损伤的脑组织与血清NO和iNOS的影响研究

目的:研究乙酰葛根素对于大鼠局灶性脑缺血再灌注损伤的脑组织与血清NO和iNOS的影响。方法:使用MCAO(大脑中动脉内拴线阻断法)测定大鼠局灶性缺血再灌注损伤模型,并观察脑组织与血清NO、血清iNOS的水平变化。结果:在小鼠脑缺血1h,再灌注24 h后,其血清NO以及iNOS水平上升显著;再灌注48h后,给予250、50、10 mg.kg~(-1)的乙酰葛根素以及葛根素组的小鼠血清NO、iNOS含量呈现出明显下降的趋势,P0.05,差异具有统计学意义。结论:将乙酰葛根素应用于治疗大鼠局灶性脑缺血再灌注损伤的过程中,能通过降低NO毒性起到保护脑组织的作用,从而减轻脑缺血再灌注损伤症状。     

阴道镜直视下宫颈活检诊断CINII中漏诊CINII以上病变的研究及意义

目的:评价阴道镜直视下活检诊断CINII的准确性,分析影响漏诊CINII以上病变(简称CINII~+)的相关因素,并探讨P16~(INK4a)蛋白表达在预测漏诊CINII~+中的价值。方法:回顾分析2013年12月至2015年7月在南京医科大学第一附属医院宫颈病中心阴道镜直视下宫颈活检诊断为CINII,且在短期内行LEEP的148例患者。研究患者手术前后病理诊断,同时对患者年龄、初次TCT结果、高危型HPV负荷量、阴道镜下病变累及宫颈象限数、转化区类型、阴道镜图像表现以及CINII组织中P16~(INK4a)蛋白表达等与漏诊CINII~+的关系进行单因素及多因素分析。结果:(1)阴道镜直视下活检诊断的148例CINII中,71例(49.97%)漏诊CINII~+,其中1例宫颈鳞癌IA1期,1例宫颈鳞癌IB1期。单因素分析显示,患者年龄、初次TCT结果、高危型HPV负荷量、阴道镜下病变累及象限数、转化区类型、阴道镜图像特征与CINII~+病变漏诊无明显相关性(P0.05),CINII组织中P16~(INK4a)蛋白表达与CINII~+病变漏诊明显相关(P0.05)。多因素分析显示,P16~(INK4a)蛋白阳性表达是影响阴道镜直视下活检诊断CINII漏诊CINII~+的危险因素(OR=9.846,95%CI为2.165~44.787;P=0.003)。(2)21例(14.19%)P16~(INK4a)蛋白呈阴性表达,127例(85.81%)呈阳性表达。P16~(INK4a)蛋白表达阴性组中漏诊CINII~+3例(14.29%),P16~(INK4a)蛋白表达阳性组中漏诊CINII~+68例(53.54%),两组比较差异有统计学意义(P0.05)。P16~(INK4a)阳性表达预测漏诊CINII~+的敏感性95.77%,特异性为23.38%,阴性预测值为85.71%,阳性预测值为53.54%。结论:阴道镜直视下活检诊断的CINII中存在CINII~+的漏诊,而CINII并P16~(INK4a)蛋白阳性表达是影响CINII~+漏诊的危险因素,对P16~(INK4a)蛋白表达阳性的CINII患者的临床干预存在其合理性。针对CINII的个体化管理,需综合考虑患者的年龄、P16~(INK4a)蛋白表达、对生育功能保护的需求及随访的依从性。     

超敏C-反应蛋白检测的临床应用

目的探讨超敏C-反应蛋白(hs-CRP)检测在临床多种疾病诊断和鉴别诊断中的意义。方法采用OLYMPUSLL AU-400全自动生化分析仪,芬兰Orion Diagnostica公司hs-CRP试剂盒,检测我院门诊及住院病人共3 720例。结果细菌感染者hs-CRP显著增高,心血管疾病患者明显增高,病毒感染、糖尿病、子宫肌瘤、宫外孕等疾病血清浓度变化不大或基本保持不变。结论hs-CRP测定能准确快速地判断引起感染的病原体类别,对疾病的诊断鉴别诊断具有一定的价值。     

成人Still’s病1例

患者 ,男 ,4 7岁 ,因持续发热、咽痛、一过性皮疹、四肢大关节疼痛 30天于 1998年 5月 2 8日入院。患者30天前出现发热 (T37.8～ 38.5℃ )、咽痛、头痛、全身疲乏不适 ,自服安必仙胶囊、克感敏 3天 ,无效 ,且咽痛更甚。又静滴青霉素钠 80 0万U2天 ,咽痛减轻 ,但发热不退 ,且出现四肢大关节肿痛、麻木。继续静滴青霉素钠 4天 ,咽痛、关节痛仍反复发作 ,体温呈弛张热(T38～ 4 0℃ ) ,且关节肿痛随体温升高而加剧。发病第 9天 ,双腕、双膝、双髋关节周围皮肤出现环形红斑样皮疹 (如红墨水涂抹 ) ,持续 2天 ,皮疹逐渐消退 ,但发热、咽痛、关节…     

Trivex静脉旋切系统在静脉性溃疡治疗中的应用

目的：探讨使用Trivex静脉旋切系统行深筋膜下小腿交通支静脉旋切治疗下肢静脉性溃疡的可行性和临床疗效。方法：本组24例（28条肢体）下肢静脉性溃疡患者常规行大小隐静脉高位结扎后激光或射频腔内闭合浅静脉主干，使用Trivex静脉旋切系统行深筋膜下小腿交通支静脉旋切和浅筋膜下曲张静脉旋切。结果：术后全组患者症状均有明显改善，溃疡均在8～28d基本愈合（平均14．5d）。结论：Trivex静脉旋切系统治疗下肢静脉性溃疡创伤小，结合激光和射频治疗闭合浅静脉主干，疗效确切，值得推广：